#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#
CS
proLékaře.cz / Journals / General Practitioner / 2024 - 5-6

Definition, classification and incidence of pulmonary arterial hypertension

Czech version

Authors: H. Al-Hiti
Published in: Prakt. Lék. 2024; 104(5-6): 227-234
Category: Reviews

Overview

Al-Hiti H. Definition, classification and incidence of pulmonary arterial hypertension

Pulmonary arterial hypertension leads to hypertrophy, dilatation of the right ventricle and ultimately to heart failure. Patients are still diagnosed in advanced stages of the disease, most often in NYHA classification III. and IV. stages. Untreated pulmonary arterial hypertension has a fatal impact on the fate of patients. The aim of this work is to introduce a new definition, classification, epidemiological data and treatment options.

Keywords:

Pulmonary hypertension – pulmonary arterial hypertension – treatment of pulmonary arterial hypertension

Sources
  1. Herget J, Hampl V. Pulmonary circulation. In: Šrámek BB, Valenta J, Klimeš F (eds.) Biomechanice of the Cardiovascular System. Prague: Czech Technical University Press 1995; 327– 336.
  2. Reeves JT, Groves BM. Approach to the patient with pulmonary hypertension. In: Weir EK, Reeves JT. (eds). Pulmonary hypertension. Mount Kisco: Futura 1984; 1–44.
  1. Weir EK, Archem SL, Rubin LJ. Pulmonary hypertension. In: Willerson JT, John JN, (Eds.) Cardiovascular medicine. New York: Churchill Livingstone, 1995; 1495–1523.
  2. Widimský J, Widimský P. Základy invazivní hemodynamiky. Praha: Triton 1999.
  3. Epson Y. The normal pulmonary circulation. In: Baum GL, Dolinsky E. (eds.) Textbook of pulmonary diseases. Boston/Toronto: Little, Brown and Company 1989.
  4. Grossmann W, Braunwald E. Pulmonary hypertension. In: Braunwald E. (ed.). Heart disease – a textbook of cardiovascular medicine. 4th ed. Philadelphia: W.B. Saunders Comp 1992.
  5. Widimský J. Patofyziologie krevního oběhu: In: Fejfar Z., Přerovský I. a spol. Patofyziologie krevního oběhu. Praha: Avicenum 1980.
  6. Kovacs G, Berghold A, Scheidl, S, Olschewski H. Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review. Eur Respir J. 2009; 34: 888–894.
  7. Mandel J, Taichman D. Pulmonary vascular disease. Philadelphia: Saunders Comp. 2006.
  8. Dresdale DT, Schultz M, Nichrom RJ. Primary pulmonary hypertension. I Clinical and hemodynamic study. Am J Med. 1951; 11: 686–705.
  9. Wagenvoort CA, Wagenvoort N. Primary pulmonary hypertension: a pathologic study of the lung vessels in 156 cliniically diagnosed cases. Circulation 1970; 42: 1163–1184.
  10. Hatano S. Primary pulmonary hypertension. Report on a WHO meeting. Geneva 1973.
  11. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med. 1987; 107: 216–223.
  12. Rich S. (ed.). Primary pulmonary hypertension: Executive Summary from the World Symposium. Evian 1988 [online]. Dostupné z: http://www.wsphassociation.org/wp-content/up- loads/2019/04/Primary-Pulmonary-Hypertension-Evian-1998. pdf [cit. 2024-11-25].
  13. Humber M, Kovac G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022; 43: 3618–3731.
  14. Galie N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016; 37(1): 67–119.
  15. Badesch DB, Raskob GE, Elliott CG, et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest 2010; 137(2): 376–387.
  16. Chung L, Farber HW, Benza R, et al. Unique predictors of mortality in patients with pulmonary arterial hypertension associated with systemic sclerosis in the REVEAL registry. Chest 2014; 146(6): 1494–1504.
  17. Benza RL, Miller DP, Gomberg-Maitland M, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 2010; 122(2): 164–172.
  18. Butler J, Chomsky DB, Wilson JR. Pulmonary hypertension and exercise intolerance in patients with heart failure. J Am Coll Cardiol. 1999; 34(6): 1802–1806.
  19. Rich S, Kaufmann E, Levy PS. The effect of hight doses of kalcium-chanel blockers on surfoval in primary pulmonary hypertension. N Engl J Med. 1992; 327: 76–81.
  20. Groves BM, Badesch DM, Turkevich D, et al. Correlation of acute prostacyclin response in primary (unexplained) pulmonary hypertension with efficacy of treatment with calcium channel blockers and survival. In: Weir K (ed). Ion flux in pulmonary vascular control. New York, NY: Plenum Press 1993; 317–330.
  21. Schrader BJ, Invar S, Kaufmann L, et al. Comparison of the effect of adenosine and nifedipine in pulmonary hypertension. J Am Coll Cardiol. 1992; 29: 1060–1064.
  22. Sitbon O, Hubert M, Jagot JL, et al. Inhaled nitric oxide as a screening agent for safety identifying responders to oral calcium-chanel blockers in primary pulmonary hypertension. Eur Respir J. 1998; 12: 265–270.
  23. Opitz CF, Wensel R, Bettmann M, et al. Assessment of the vasodilator response in primary pulmonary hypertension: comparing prostacyclin and iloprost administered by either infusion or inhalation. Eur Heart J. 2003; 24: 356–365.
  24. Sitbon O, Hubert M, Ioos V, et al. Who benefits from long-term calcium-chanel blockers therapy in primary pulmonary hypertension. Am J Respir Crit Care Med. 2003; 167: A440.
  25. Franak H, Mlczoch, Huber K, et al. The effect of anticoagulant therapy in primary and anorectic drug-included pulmonary hypertension. Chest 1997; 112: 714–421.
  26. Sandoval J, Gaspar J, Pulido T, et al. Graded balloon dilation atrial septostomy in severe primary pulmonary hypertension. A therapeutic alternative for patients nonresponsive to vasodilatator treatment. J Am Coll Cardiol. 1998; 32: 297–304.
  27. Trulock EP, Edwards LB, Taylor DO, et al. The Registry of International Society for Heart and Lung Transplantation: Twentyfirst official adult lung and heart transplant report-2004. J Heart Transplant. 2004; 23: 804–815.
  28. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group (see comments). N Engl J Med. 1996; 334: 296–302.
  29. Simonneau G, Barts RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterila hypertension. A double-blind, randomized, placebo-contolled trial. Am J Respir Crit Care Med. 2002; 165: 800–804.
  30. Nagaya N, Uematsu M, Okano Y, et al. Effects of beraprost sodium, an oral prostacyclin analogue on survival of outpatients with primary pulmonary hypertension. J Am Coll Cardiol. 1999; 34: 1188–1192.
  31. Olschewski H, Simonneau G, Galie N, et al. Inhaled iloprost in severe pulmonary hypertension. N Engl J Med. 2002; 347: 22–329.
  32. Pulido T, Adzerikho I, Channick RN, et al. SERAPHIN Investigators. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013; 369(9): 809–818.
  33. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002; 346: 869–903.
  34. Rubin LJ, Galie N, Badesch BD, et al. Ambisertan improves exercise kapacity and clinical measures in pulmonary arterial hypertension (PAH). Am J Respir Crit Care Med. 2004; 169: A210.
  35. Pulido T, Adzerikho I, Channick RN, et al. SERAPHIN Investigators. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013; 369(9): 809–818.
  36. Ghofrani HA, Rose F, Schermuly RT, et al. Oral sidenafil as longterm adjunkt therapy to inhaled iloprost in severe pulmonary arterial hypertension. J Am Coll Cardiol. 2003; 42: 158–164.
  37. Galie N, Brundage BH, Ghofrani HA, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009; 119: 2894–2903.
  38. Ghofrani HA, Galiè N, Grimminger F, et al; PATENT-1 Study Group. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med. 2013; 369(4): 330–340.
  39. Hoeper M.M, Badesch D.B, Ghofrani A et al. Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension. N Engl J Med. 2023; 388: 1478–1490.
Labels
General practitioner for children and adolescents General practitioner for adults
Treatment of osteoporosis by an outpatient specialist
Adenocarcinoma of the skin arising in the capillitium – a diagnostic dilemma in the biopsy practice
Tako-tsubo syndrome – a broken heart is not just a metaphor
Subtotal choroidal ablation in patient with posterior scleritis
. In 1834 Purkyně’s efforts to return to his homeland begin
Antoine-Laurent de Lavoisier (1743–1794)
Pokyny pro autory
Register 2024
Article was published in

General Practitioner

Issue 5-6
2024 Issue 5-6
Most read in this issue
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#